Comparison of plasma and tissue levels of ZD1694 (Tomudex), a highly polyglutamatable quinazoline thymidylate synthase inhibitor, in preclinical models

British Journal of Cancer

Volumn 77, Issue 2, 1998, Pages 221-226

  Aherne, G W ^a   Ward, E ^a   Lawrence, N ^a   Dobinson, D ^a   Clarke, S J ^a   Musgrove, H ^a   Sutcliffe, F ^b   Stephens, T ^b   Jackman, A L ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Pharmacokinetics; Polyglutamation; Radioimmunoassay; Thymidylate synthase inhibitor; ZD1694 (Tomudex, raltitrexed)

Indexed keywords

ANTIBODY; POLYGLUTAMIC ACID; QUINAZOLINE DERIVATIVE; RALTITREXED; THYMIDYLATE SYNTHASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CROSS REACTION; DOG; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG LIVER LEVEL; DRUG POTENCY; DRUG TISSUE LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTESTINE EPITHELIUM; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; KIDNEY; LEUKEMIA L 1210; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

EID: 0031963985     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.37     Document Type: Article

References (34)

1. Aherne GW, Piall EM and Marks V (1977) Development and application of a radioimmunoassay for methotrexate. Br J Cancer 36: 608-617
2. Aherne GW, Hardcastle A, Raynaud F and Jackman AL (1996a) Immunoreactive dUMP and TTP pools as an index of thymidylate synthase inhibition; effect of Tomudex (ZD1694) and a non-polyglutamated quinazoline antifolate (CB30900) in L1210 mouse leukaemia cells. Biochem Pharmacol 51: 1293-1301
3. Aherne GW, Ward E, Dobinson D, Hardcastle A and Jackman AL (1996b) Pharmacokinetics of a bolus injection of ZD9331, a non-polyglutamated thymidylate synthase (TS) inhibitor. Proc Am Assoc Cancer Res 37: 382
4. Anzai T, Jaffe N and Wang Y-E (1987) Separation and identification of methotrexate and its metabolites, 7-hydroxymethotrexate and polyglutamates, in human tissues by reversed-phase high-performance liquid chromatography coupled with radioimmunoassay. J Chromatography 415: 445-449
5. 10-propargyl-5,8-dideazafolic acid (ICI198583). In Chemistry and Biology of Pteridines and Folates, Vol. 338, Ayling JE, Nair MG and Baugh CM, (eds), pp. 593-596. Plenum Press: New York
6. Bisset GMF, Pawelczak K, Jackman AL, Calvert AH and Hughes LR (1992) The synthesis and thymidylate synthase inhibitory activity of the poly-γ-glutamyl) conjugates of ICI D1694 and other quinazoline antifolates. J Med Chem 35: 859-866
7. Clarke SJ, Hanwell J, deBoer M, Planting A, Verweij J, Walker M, Smith R, Jackman AL, Hughes LR, Harrap KR, Kennealy GT and Judson IR (1996) Phase 1 trial of ZD1694 ("Tomudex"), a new folate based thymidylate synthase inhibitor, in patients with solid tumours. J Clin Oncol 14: 1495-1503
8. Cunningham D, Zalcberg JR, Rath U, Olver I, van Cutsem E, Svensson C, Seitz JF, Harper P, Kerr D, Perez-Manga G, Azab M, Seymore L, Lowery K and the Tomudex Colorectal Cancer Study Group (1995) Tomudex (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. Eur J Cancer 31A: 1945-1953
9. Farrugia D, Cunningham D, Danenberg P, Danenberg K, Metzger R, Mitchell F, MacVicar D, McCarthy K, Aherne GW, Norman A and Jackman AL (1997) A pharmacodynamic (PD) study of the thymidylate synthase (TS) inhibitor Tomudex in advanced colorectal cancer (CRC). Proc Am Assoc Cancer Res 38: 615
10. Gibson W, Bisset GMF, Marsham PR, Kelland LR, Judson IR and Jackman AL (1993) The measurement of polyglutamate metabolites of the thymidylate synthase inhibitor, ICI D1694, in mouse and human cultured cells. Biochem Pharmacol 45: 863-869
11. Goker E, Lin JT, Trippett T, Elisseyeff Y, Tong WP, Niedzwiecki D, Tan C, Steinherz P, Schweitzer BI and Bertino JR (1993) Decreased polyglutamylation of methotrexate in acute lymphoblastic leukemia blasts in adults compared to children with this disease. Leukemia 7: 1000-1004
12. Hardcastle A, Dobinson D, Farrugia D, Jackman AL and Aherne GW (1997) In vivo pharmacokinetic and pharmacodynamic studies of two specific thymidylate synthase (TS) inhibitors. Br J Cancer 75 (suppl. 1): 25
13. Hughes LR, Jackman AL, Oldfield J, Smith RC, Burrows KD, Marsham PR, Bishop JAM, Jones TR, O'Connor BM and Calvert AH (1990) Quinazoline antifolate thymidylate synthase inhibitors: alkyl, substituted alkyl and aryl substituents in the C2 position. J Med Chem 33: 3060-3067
14. Jackman AL and Calvert AH (1995) Folate-based thymidylate synthase inhibitors as anticancer drugs. Ann Oncol 6: 871-881
15. Jackman AL, Taylor GA, Calvert AH and Harrap KR (1984) Modulation of antimetabolite effects: effects of thymidine on the efficacy of the quinazoline-based thymidylate synthetase inhibitor, CB3717. Biochem Pharmacol 33: 3269-3275
16. Jackman AL, Taylor GA, Gibson W, Kimbell R, Brown M, Calvert AH, Judson IR and Hughes LR (1991a) ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: new agent for clinical study. Cancer Res 51: 5579-5586
17. Jackman AL, Jodrell DI, Gibson, W and Stephens TC (1991b) ICI D1694, an inhibitor of thymidylate synthase for clinical study. In Purine and Purimidine Metabolism in Man, Vol. VII, part A, pp. 19-23. Plenum Press: New York
18. 10-propargyl-5,8-dideazafolic acid (ICI 198583). Biochem Pharmacol 42: 1885-1895
19. Jackman AL, Farrugia DC, Gibson W, Kimbell R and Harrap KR (1995a) ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer. Eur J Cancer 31A: 1277-1282
20. Jackman AL, Kimbell R, Brown M, Brunton L and Boyle FT (1995b) Quinazoline thymidylate synthase inhibitors: methods for assessing the contribution of polyglutamation to their in vitro activity. Anti-Cancer Drug Design 10: 555-572
21. Jackman AL, Kelland LR, Kimbell R, Brown M, Gibson W, Aherne GW, Hardcastle A and Boyle FT (1995c) Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines. Br J Cancer 71: 914-924
22. Jackman AL, Farrugia DC, Clarke SJ, Aherne GW, Boyle FT, Seymore L, Azab M and Kennealey G (1995d) Delayed rescue of ZD1694 toxicity in Balb/c mice with thymidine (dThd) or Leucovorin (LV). Proc Am Assoc Cancer Res 36: 377
23. Jodrell DI, Newell DR, Gibson W, Hughes LR and Calvert AH (1991) The pharmacokinetics of the quinazoline antifolate ICI D1694. Cancer Chemother Pharmacol 28: 331-338
24. Jolivet J, Schilsky RL, Bailey BD, Drake JC and Chabner BA (1982) Synthesis, retention and biological activity of methotrexate polyglutamates in cultured human breast cancer cells. J Clin Invest 70: 351-360
25. Judson IR, Aherne GW, Maughan T, Cunningham D, Hanwell J, Berry C and Walker M (1996) Pharmacokinetic studies with Tomudex (ZD1694). Ann Oncol 7 (suppl. 1): 88
26. Levine L and Powers E (1974) Radioimmunoassay for methotrexate. Res Commun Chem Path Pharmacol 9: 543-554
27. Nord DN and Martin DS (1993) Enhancement of thymidylate synthase inhibition. Curr Opinion Oncol 5: 1017-1022
28. Pizzorno G, Chang Y-M, McGuire JJ and Bertino JR (1989) Inherent resistance of squamous carcinoma cell lines to methotrexate as a result of decreased polyglutamation of this drug. Cancer Res 49: 5275-5280
29. Samuels LL, Feinberg A, Moccio DM, Sirotnak FM and Rosen G (1984) Detection by high-performance liquid chromatography of methotrexate and its metabolites in tumour tissue from osteosarcoma patients treated with high-dose methotrexate/leucovorin rescue. Biochem Pharmacol 33: 2711-2714
30. Schalhorn A, Sauer H, Wilmanns W and Stupp-Poutot G (1982) Pharmacokinetics of erythrocyte methotrexate after high-dose methotrexate. Cancer Chemother Pharmacol 9: 65-69
31. 10-propargyl-5,8-dideazafolic acid polyglutamates in tumour cells. Anal Biochem 172: 344-355
32. Smith I, Jones A, Spielmann M, Namer M, Green MD, Bonneterre J, Wander HE, Hatschek T, Wilking N, Zalcberg J, Spiers J and Seymore L (1996) A phase II study in advanced breast cancer: ZD1694 (Tomudex) a novel direct and specific thymidylate synthase inhibitor. Br J Cancer 74: 479-481
33. Walton MI, Gibson W, Aherne GW, Lawrence N, Stephens TC, Smith MN and Jackman AL (1996) Preclinical pharmacology of CB30900, a novel dipeptide inhibitor of thymidylate synthase, in mice. J Exp Ther Pharmacol 277: 909-916
34. Zalcberg J, Cunningham D, Green M, Francois E, Van Cutsem E, Schornagel J, Adenis A, Seymore L and Azab M (1995) The final results of a large Phase II study of the potent thymidylate synthase (TS) inhibitor Tomudex (ZD1694) in advanced colorectal cancer. Proc Am Soc Cancer Res 4: 204